NASDAQ:AKRX - Akorn Stock Price, Forecast & News

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

Akorn, Inc. (NASDAQ:AKRX) issued its quarterly earnings results on Thursday, October, 31st. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.06. The firm earned $176.24 million during the quarter, compared to analyst estimates of $176.15 million. Akorn had a negative return on equity of 19.95% and a negative net margin of 53.62%. The firm's quarterly revenue was up 6.4% on a year-over-year basis. During the same period last year, the company posted ($0.06) EPS. View Akorn's Earnings History.

3 Wall Street analysts have issued 1-year price targets for Akorn's shares. Their forecasts range from $4.00 to $8.00. On average, they anticipate Akorn's share price to reach $5.67 in the next year. This suggests a possible upside of 384.3% from the stock's current price. View Analyst Price Targets for Akorn.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Akorn.

Media coverage about AKRX stock has been trending extremely negative recently, InfoTrie reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akorn earned a news sentiment score of -4.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Akorn.

Akorn saw a increase in short interest in February. As of February 14th, there was short interest totalling 6,940,000 shares, an increase of 14.3% from the January 30th total of 6,070,000 shares. Based on an average trading volume of 2,760,000 shares, the days-to-cover ratio is currently 2.5 days. Approximately 7.0% of the company's shares are short sold. View Akorn's Current Options Chain.

Some companies that are related to Akorn include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Akorn's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (8.38%), Canyon Capital Advisors LLC (3.96%), State Street Corp (2.67%), Geode Capital Management LLC (1.51%), Connor Clark & Lunn Investment Management Ltd. (1.03%) and Maverick Capital Ltd. (0.98%). Company insiders that own Akorn stock include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Institutional Ownership Trends for Akorn.

AKRX stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Spark Investment Management LLC, Assenagon Asset Management S.A., Connor Clark & Lunn Investment Management Ltd., UBS Group AG and Bank of America Corp DE. View Insider Buying and Selling for Akorn.

AKRX stock was purchased by a variety of institutional investors in the last quarter, including Canyon Capital Advisors LLC, Maverick Capital Ltd., Renaissance Technologies LLC, Marshall Wace LLP, Marshall Wace North America L.P., Geode Capital Management LLC, Oxford Asset Management LLP and Gabelli Funds LLC. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Insider Buying and Selling for Akorn.

Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKRX stock can currently be purchased for approximately $1.17.

Akorn has a market capitalization of $147.59 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe.View Additional Information About Akorn.

The official website for Akorn is http://www.akorn.com/.

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]